Rat CD25/IL-2R alpha Alexa Fluor® 350-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB51561U
Key Product Details
Species Reactivity
Applications
Label
Antibody Source
Product Specifications
Immunogen
Glu22-Gln235
Accession # P26897
Specificity
Clonality
Host
Isotype
Applications for Rat CD25/IL-2R alpha Alexa Fluor® 350-conjugated Antibody
Flow Cytometry
Sample: Rat splenocytes
Formulation, Preparation, and Storage
Purification
Formulation
Shipping
Stability & Storage
Background: CD25/IL-2R alpha
IL-2 receptor alpha (IL-2 R alpha), also known as CD25, is a 55 kDa type I membrane glycoprotein that belongs to the family of cytokine receptors that utilize the common gamma chain subunit ( gammac). IL-2 R alpha is primarily expressed on activated T cells and on regulatory T cells (Treg) (1 - 3). The rat IL-2 R alpha cDNA encodes a 267 amino acid (aa) precursor that includes a 21 aa signal peptide, a 214 aa extracellular domain (ECD) with two Sushi domains, a 21 aa transmembrane segment, and an 11 aa cytoplasmic domain (4). Within the ECD, rat IL-2 R alpha shares 58% and 81% aa sequence identity with human and mouse IL-2 R alpha, respectively. It shares approximately 15% aa sequence identity with IL-4, -7, -9, -15, and -21 receptor subunits that also complex with gammac. IL-2 R beta (CD122) and gammac (IL-2 R gamma/CD132) dimerize to form a constitutively expressed intermediate affinity IL-2 receptor (5, 6). By itself, IL-2 R alpha binds IL-2 with low affinity. It associates with IL-2 R beta and gammac to generate a ternary high affinity IL-2 receptor complex (7). A soluble form of IL-2 R alpha can be generated by proteolytic cleavage of the cell surface receptor, rendering the T cell unresponsive to IL-2 (8, 9). Increased serum levels of soluble IL-2 R alpha are found in some cancers and immune disorders (10). IL-2 R alpha is required for activation induced cell death (AICD) of naive T cells, a mechanism responsible for deleting autoreactive T cell clones (11, 12). IL-2 R alpha is also required for the development of CD4+CD25+ Treg which suppress autoreactive CD4+ T cells, thereby contributing to peripheral T cell homeostasis (11-13).
References
- Minami, Y. et al. (1993) Annu. Rev. Immunol. 11:245.
- Kovanen, P.E. and W.J. Leonard (2004) Immunol. Rev. 202:67.
- Bluestone, J.A. and Q. Tang (2005) Curr. Opin. Immunol. 17:638.
- Page, T.H. and M.J. Dallman (1991) Eur. J. Immunol. 21:2133.
- Hatakeyama, M. et al. (1989) Science 244:551.
- Takeshita, T. et al. (1992) Science 257:379.
- Wang, X. et al. (2005) Science 310:1159.
- Wagner, D.K. et al. (1986) J. Immunol. 137:592.
- Schulz, O. et al. (1998) J. Exp. Med. 187:271.
- Witkowska, A.M. (2005) Mediators Inflamm. 2005:121.
- Willerford, D.M. et al. (1995) Immunity 3:521.
- Van Parijs, L. et al. (1997) J. Immunol. 158:3738.
- Almeida, A.R.M. et al. (2002) J. Immunol. 169:4850.
Long Name
Alternate Names
Entrez Gene IDs
Gene Symbol
UniProt
Additional CD25/IL-2R alpha Products
Product Documents for Rat CD25/IL-2R alpha Alexa Fluor® 350-conjugated Antibody
Product Specific Notices for Rat CD25/IL-2R alpha Alexa Fluor® 350-conjugated Antibody
This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.
For research use only